3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Endocrine
1
Conditions
Carcinoma, Non-Small-Cell Lung
115
Breast Neoplasms
113
Ovarian Neoplasms
71
Triple Negative Breast Neoplasms
56
Fallopian Tube Neoplasms
42
Endometrial Neoplasms
42
Squamous Cell Carcinoma of Head and Neck
39
Lung Neoplasms
38
Neoplasm Metastasis
35
Stomach Neoplasms
28
Neoplasms
28
Parkinson Disease 4, Autosomal Dominant Lewy Body
27
Esophageal Neoplasms
22
Esophageal Squamous Cell Carcinoma
21
Head and Neck Neoplasms
16
Carcinoma
16
Uterine Cervical Neoplasms
15
Carcinoma, Ovarian Epithelial
15
Colorectal Neoplasms
14
Carcinoma, Squamous Cell
11
Adenocarcinoma
10
Small Cell Lung Carcinoma
9
Adenocarcinoma Of Esophagus
9
Peritoneal Neoplasms
8
Oropharyngeal Neoplasms
8
Melanoma
8
Carcinoma, Transitional Cell
8
Urinary Bladder Neoplasms
7
Pancreatic Neoplasms
7
Mouth Neoplasms
7
Interventions
tremelimumab
4
Ipilimumab
4
lenvatinib
3
durvalumab
3
Nivolumab
3
pembrolizumab
2
balstilimab
2
Pemetrexed
2
Carboplatin
2
Bevacizumab
2
spartalizumab
1
relatlimab
1
poly ICLC
1
osimertinib
1
cemiplimab
1
Vemurafenib
1
Vascular Endothelial Growth Factor A
1
Standard of Care
1
Platinum
1
Peptides
1
Paclitaxel
1
Opdualag
1
Docetaxel
1
Capecitabine
1
Blood Specimen Collection
1
Axitinib
1
Antibodies, Bispecific
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Diabetes Mellitus, Insulin-Dependent, 12
×
Paclitaxel
×
1 year
×
Clear all
NCT05142189
2026-04-14
LuCa-MERIT-1
BioNTech SE
Phase 1
Recruiting
320 enrolled